Unilife to Supply Hikma with Prefilled Syringes for Generic Injectables - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Unilife to Supply Hikma with Prefilled Syringes for Generic Injectables
Unilife to begin commercial supply in 2014.

Unilife Corporation, a US-based developer and commercial supplier of injectable drug-delivery systems, has signed a 15-year agreement with Hikma Pharmaceuticals, in which Unilife will supply customized prefilled syringes to Hikma for a range of generic injectable drugs.

Hikma has selected an initial list of 20 generic injectable products to be formulated using Unilife’s proprietary platform (branded as Unifill) of prefilled syringes with automatic and fully integrated needle retraction.

Under the terms of the agreement, Hikma holds exclusive global rights to its generic products using Unilife’s Unifill platform. Additional injectable drugs may also be added to the exclusivity list subject to agreement by both parties.

In return, Unilife will receive $40 million in upfront and milestone payments. An initial upfront payment of $5 million will be paid to Unilife immediately, with an additional $15 million in payments expected during 2014. The final $20 million in milestone-based payments will be paid the following year.

Unilife will start supplying the products to Hikma in early 2014, with a minimum supply volume expected to exceed 175 million units per year.

Source: Unilife


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns

Click here